Denali Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Denali Therapeutics Inc. (DNLI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 1.90% for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2019-11-06
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-09-30 was 1.90%, a 34.48% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-06-30 was 2.30%, a 20.69% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-03-31 was 2.60%, a 3.70% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-09-30 was 2.90%, a 52.63% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2018 was 3.10%, a 34.78% increase from fiscal 2017.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.30%, a 9.52% increase from fiscal 2016.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2016 was 2.10%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2019-09-30 | 1.90% 10-Q · filed 2019-11-06 | 2.60% 10-Q · filed 2019-11-06 | ||
| 2019-06-30 | 2.30% 10-Q · filed 2019-08-06 | 2.60% 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | 2.60% 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | 3.10% 10-K · filed 2019-03-12 | |||
| 2018-09-30 | 2.90% 10-Q · filed 2019-11-06 | 2.90% 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | 2.90% 10-Q · filed 2019-08-06 | 2.90% 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | 2.70% 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | 2.30% 10-K · filed 2019-03-12 | |||
| 2017-09-30 | 1.90% 10-Q · filed 2018-11-08 | 2.30% 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | 2.30% 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | 2.30% 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | 2.10% 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |